Clinical Efficacy and Safety of Intravesical Infusion of Gemcitabine and Pirarubicin in Preventing Recurrence of Bladder Cancer after Operation
This paper explores the clinical efficacy and safety of intravesical infusion of gemcitabine and pirarubicin in preventing recurrence of bladder cancer after operation. 66 patients were divided into control group and research group according to the order of admission. 33 patients in each group were given gemcitabine intravesical instillation chemotherapy after operation in control group and gemcitabine and piperidine after operation in study group. The efficacy and safety of sequential intravesical infusion of rubicin were compared. Result shows thatone-year recurrence rate of the control group was 12.12%, the one-year recurrence rate of the study group was only 6.06%, the difference between the two groups was significant (P < 0.05); the two-year recurrence rate of the control group was 21.21%, the two-year recurrence rate of the study group was only 12.12%, the difference between the two groups was significant (P < 0.05); The incidence of hematuria, fever, urgency, pain and frequency of urination was 15.15% in the control group and 30.30% in the control group, which was significantly higher than that in the study group. The difference between the two groups was significant (P < 0.05). Gemcitabine and pirarubicin sequential intravesical instillation chemotherapy has good effect in preventing recurrence of bladder cancer after operation. It can effectively control recurrence of bladder cancer and has good safety. There are few adverse reactions such as hematuria, fever, urgency of urine during the treatment of patients. It is worth promoting in clinical practice.